Explore why the PharmAla and Jupiter Neurosciences licensing deal could reshape investor sentiment around next-generation psychedelic therapeutics.
Home care demand is rising, but margins remain tight. Enhabit’s Kinderhook exit tests whether private equity can unlock scale without care risk.
Could TN-401 change ARVC treatment strategy? Explore what Tenaya Therapeutics, Inc.’s RIDGE-1 data means for cardiac gene therapy.
Single-use catheters finally face a regulated reuse challenge. Aurie’s FDA De Novo win could shift urology device economics.
Actuate Therapeutics, Inc. is advancing oral elraglusib after FDA IND clearance. Discover what this means for pancreatic cancer economics.
Could fully implanted cochlear implants transform hearing restoration? Explore the regulatory, clinical, and market implications now.
Cryo-Cell avoided immediate delisting pressure. The harder test is whether its cord blood banking model can repair the balance sheet by 2027.
ADC ambition meets Keytruda dominance. Kelun-Biotech’s sac-TMT filing could test how far TROP2 combinations can move in lung cancer.
Curaleaf is adding Florida stores as cannabis investors demand proof of profitable scale. The next test is store productivity, not footprint.
Artivion’s aortic portfolio is getting stronger, but its 2026 outlook is getting weaker. Can Endospan turn strategy into growth?